Bank Hapoalim BM decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.6% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 32,733 shares of the biopharmaceutical company’s stock after selling 3,896 shares during the period. Bank Hapoalim BM’s holdings in Gilead Sciences were worth $2,223,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership raised its position in shares of Gilead Sciences by 648.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 107,800 shares of the biopharmaceutical company’s stock worth $7,720,000 after buying an additional 93,400 shares during the period. Barings LLC raised its position in shares of Gilead Sciences by 18.7% in the fourth quarter. Barings LLC now owns 152,842 shares of the biopharmaceutical company’s stock worth $10,945,000 after buying an additional 24,120 shares during the period. Clough Capital Partners L P raised its position in shares of Gilead Sciences by 91.8% in the fourth quarter. Clough Capital Partners L P now owns 248,322 shares of the biopharmaceutical company’s stock worth $17,782,000 after buying an additional 118,822 shares during the period. ARS Investment Partners LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $398,000. Finally, RB Capital Management LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $223,000. 74.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 73.16 on Monday. The company’s 50 day moving average price is $70.60 and its 200-day moving average price is $68.59. The firm has a market capitalization of $95.55 billion, a P/E ratio of 7.95 and a beta of 1.21. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the prior year, the business posted $3.08 earnings per share. The firm’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, equities analysts predict that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

TRADEMARK VIOLATION WARNING: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/07/bank-hapoalim-bm-has-2-22-million-stake-in-gilead-sciences-inc-nasdaqgild.html.

GILD has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Gilead Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 11th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $73.87 target price on the stock. in a research report on Tuesday, April 11th. Cowen and Company reiterated a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research report on Monday, April 17th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Eleven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $80.31.

In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total transaction of $668,666.75. Following the completion of the sale, the director now directly owns 47,562 shares in the company, valued at $3,198,544.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total value of $1,138,200.00. Following the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold 216,609 shares of company stock worth $15,891,851 over the last quarter. 1.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.